From iron chelation to overload as a therapeutic strategy to induce ferroptosis in hematologic malignancies

References

• Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Li J, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2).
   Web of Science ®Google Scholar
• Lu B, et al. The role of ferroptosis in cancer development and treatment response. Front Pharmacol. 2017;8:992.
   PubMed Web of Science ®Google Scholar
• Dai E, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020;11(1):6339.
   PubMed Web of Science ®Google Scholar
• Badgley MA, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–89.
   PubMed Web of Science ®Google Scholar
• Bottcher JP, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1037.
   PubMed Web of Science ®Google Scholar
• Mou Y, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34.
   PubMed Web of Science ®Google Scholar
• Grignano E, et al. From iron chelation to overload as a therapeutic strategy to induce ferroptosis in leukemic cells. Front Oncol. 2020;10:586530.
   PubMed Web of Science ®Google Scholar
• Kajarabille N, Latunde-Dada GO. Programmed cell-death by ferroptosis: antioxidants as mitigators. Int J Mol Sci. 2019;20(19).
   PubMed Web of Science ®Google Scholar
• Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317–331.
   PubMed Web of Science ®Google Scholar
• Lv Q, et al. Abnormal ferroptosis in myelodysplastic syndrome. Front Oncol. 2020;10:1656.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology. 2014;15(12):E538–E548.
   PubMed Web of Science ®Google Scholar
• Battipaglia G, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia: an update. Clin Lymphoma Myeloma Leukemia. 2019;19(8):506–508.
   PubMed Web of Science ®Google Scholar
• Franke GN, et al. Iron overload and its impact on outcome of patients with hematological diseases. Mol Aspects Med. 2020;75:100868.
   PubMed Web of Science ®Google Scholar
• Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk – a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev. 2014;23(1):12–31.
   PubMed Web of Science ®Google Scholar
• Lebon D, et al. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leuk Res. 2015;39(8):818–821.
   PubMed Web of Science ®Google Scholar
• Shenoy N, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873–881.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10.
   PubMed Web of Science ®Google Scholar
• Malcovati L, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–7603.
   PubMed Web of Science ®Google Scholar
• Angelucci E, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172(8):513–522.
   PubMed Web of Science ®Google Scholar
• Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
   PubMed Web of Science ®Google Scholar
• Konig C, et al. Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS– and stem cell transplant (SCT)–patients? Clin Lymphoma Myeloma Leuk. 2013;13(6):671–680.
   PubMed Web of Science ®Google Scholar
• Cottereau AS, et al. Whole-body diffusion-weighted MR imaging of iron deposits in hodgkin, follicular, and diffuse large B-cell lymphoma. Radiology. 2018;286(2):560–567.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87.
   PubMed Web of Science ®Google Scholar
• Kovacevic Z, et al. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem. 2011;11(5):483–499.
   PubMed Web of Science ®Google Scholar
• Weber S, et al. The clinical significance of iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia. Front Immunol. 2020;11:627662.
   PubMed Web of Science ®Google Scholar
• Furukawa T, et al. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci. 1992;50(26):2059–2065.
   PubMed Web of Science ®Google Scholar
• Yang Y, et al. Effects of deferoxamine on leukemia in vitro and its related mechanism. Med Sci Monit. 2018;24:6735–6741.
   PubMed Web of Science ®Google Scholar
• Leardi A, et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol. 1998;102(3):746–752.
   PubMed Web of Science ®Google Scholar
• Yalcintepe L, Halis E. Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. Bosn J Basic Med Sci. 2016;16(1):14–20.
   PubMed Web of Science ®Google Scholar
• Shapira S, et al. Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation, induction of ROS, and inhibition of HIF1alpha expression. Exp Hematol. 2019;70:55–69.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009;100(5):970–977.
   PubMed Web of Science ®Google Scholar
• Li N, et al. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562. Oncotarget. 2017;8(22):36517–36530.
   PubMedGoogle Scholar
• Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32(5):368–377.
   PubMed Web of Science ®Google Scholar
• Devin J, et al. Targeting cellular iron homeostasis with ironomycin in diffuse large B-cell lymphoma. Cancer Res. 2022;82(6):998–1012.
   PubMed Web of Science ®Google Scholar
• Kamihara Y, et al. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/beta-catenin signaling in human multiple myeloma. Oncotarget. 2016;7(39):64330–64341.
   PubMedGoogle Scholar
• Pullarkat V, et al. Iron chelators induce autophagic cell death in multiple myeloma cells. Leuk Res. 2014;38(8):988–996.
   PubMed Web of Science ®Google Scholar
• Wang Y, et al. Iron metabolism in cancer. Int J Mol Sci. 2018;20(1).
   Web of Science ®Google Scholar
• Colins A, et al. Mathematical modeling of intestinal iron absorption using genetic programming. PLoS One. 2017;12(1).
   PubMed Web of Science ®Google Scholar
• Zhou LF, et al. Alterations in cellular iron metabolism provide more therapeutic opportunities for cancer. Int J Mol Sci. 2018;19(5).
   Web of Science ®Google Scholar
• Brown RAM, et al. Altered iron metabolism and impact in cancer biology, metastasis, and immunology. Front Oncol. 2020;10:476.
   PubMed Web of Science ®Google Scholar
• Torti SV, et al. Iron and cancer. Annu Rev Nutr. 2018;38:97–125.
   PubMed Web of Science ®Google Scholar
• Lachaier E, et al. Ferroptosis, a new form of cell death relevant to the medical treatment of cancer. M S-Med Sci. 2014;30(8-9):779–783.
   Google Scholar
• Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–245.
   PubMedGoogle Scholar
• Kwon MY, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 2015;6(27):24393–24403.
   PubMedGoogle Scholar
• Wang YQ, et al. The protective role of mitochondrial ferritin on erastin-induced ferroptosis. Am J Hematol. 2017;92(8):E459–E459.
   Web of Science ®Google Scholar
• Mancias JD, et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105+.
   PubMed Web of Science ®Google Scholar
• Mancias JD, et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. eLife. 2015;4.
   PubMed Web of Science ®Google Scholar
• Hou W, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12(8):1425–1428.
   PubMed Web of Science ®Google Scholar
• Yuan H, et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem Biophys Res Commun. 2016;478(2):838–844.
   PubMed Web of Science ®Google Scholar
• Kagan VE, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015;10(7):1604–1609.
   PubMed Web of Science ®Google Scholar
• Doll S, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–98.
   PubMed Web of Science ®Google Scholar
• Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482(3):419–425.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285.
   PubMed Web of Science ®Google Scholar
• Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–176.
   PubMed Web of Science ®Google Scholar
• Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.
   PubMed Web of Science ®Google Scholar
• Yang WS, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966–E4975.
   PubMed Web of Science ®Google Scholar
• Lv HH, et al. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy. Oxid Med Cell Longevity. 2019;2019.
   Web of Science ®Google Scholar
• Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11-12):2195–2209.
   PubMed Web of Science ®Google Scholar
• Angeli JPF, Conrad M. Selenium and GPX4, a vital symbiosis. Free Radical Biol Med. 2018;127:153–159.
   PubMed Web of Science ®Google Scholar
• Mullen PJ, et al. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16(11):718–731.
   PubMed Web of Science ®Google Scholar
• Ye FH, et al. HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q)(61L) cells. Am J Cancer Res. 2019;9(4):730 + .
   PubMed Web of Science ®Google Scholar
• Zhu T, Fan Y. Autophagy regulates the sensitivity of acute lymphoblastic leukemia cells to ferroptosis activator by influencing iron homeostasis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(5):1380–1386.
   PubMedGoogle Scholar
• Zhu T, et al. Autophagy regulates VDAC3 ubiquitination by FBXW7 to promote erastin-induced ferroptosis in acute lymphoblastic leukemia. Front Cell Dev Biol. 2021;9:740884.
   PubMed Web of Science ®Google Scholar
• Schoeneberger H, et al. Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for smac mimetic-induced cell death. Oncogene. 2015;34(31):4032–4043.
   PubMed Web of Science ®Google Scholar
• Metzelder SK, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017;86:233–239.
   PubMed Web of Science ®Google Scholar
• Du J, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radical Biol Med. 2019;131:356–369.
   PubMed Web of Science ®Google Scholar
• Fox JM, et al. Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget. 2016;7(6):7268–7279.
   PubMedGoogle Scholar
• Namvar F, et al. Cytotoxic effect of magnetic iron oxide nanoparticles synthesized via seaweed aqueous extract. Int J Nanomed. 2014;9:2479–2488.
   PubMed Web of Science ®Google Scholar
• Cao K, et al. Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small. 2022;18(13):e2106558.
   PubMed Web of Science ®Google Scholar
• Zhang Y, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;26(5):623–633.
   PubMed Web of Science ®Google Scholar
• Zhong Y, et al. FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells. Life Sci. 2020;260:118077.
   PubMed Web of Science ®Google Scholar
• Liu Q, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leuk Lymphoma. 2014;55(4):892–898.
   PubMed Web of Science ®Google Scholar
• Wu B, et al. Clinical value of high expression level of CD71 in acute myeloid leukemia. Neoplasma. 2016;63(5):809–815.
   PubMed Web of Science ®Google Scholar
• Kawabata H, et al. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood. 2001;98(9):2714–2719.
   PubMed Web of Science ®Google Scholar
• Nakamaki T, et al. Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. Br J Haematol. 2004;125(1):42–49.
   PubMed Web of Science ®Google Scholar
• Bauvois B, Susin SA. Revisiting neutrophil gelatinase-associated lipocalin (NGAL) in cancer: saint or sinner? Cancers (Basel). 2018;10(9).
   PubMed Web of Science ®Google Scholar
• Yang WC, et al. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2013;54(8):1614–1625.
   PubMed Web of Science ®Google Scholar
• Bertoli S, et al. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. Eur J Haematol. 2019;102(2):131–142.
   PubMed Web of Science ®Google Scholar
• Trujillo-Alonso V, et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019;14(6):616–622.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, et al. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019;80:1–10.
   PubMed Web of Science ®Google Scholar
• Dachert J, et al. RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death. Oncotarget. 2016;7(39):63779–63792.
   PubMedGoogle Scholar
• Probst L, et al. Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. Biochem Pharmacol. 2017;140:41–52.
   PubMed Web of Science ®Google Scholar
• Yu Y, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2(4):e1054549.
   PubMed Web of Science ®Google Scholar
• Battipaglia G, et al. Efficacy and feasibility of sorafenib As a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia. Blood. 2016;128(22).
   Google Scholar
• Kinowaki Y, et al. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab Invest. 2018;98(5):609–619.
   PubMed Web of Science ®Google Scholar
• Chen Y, et al. Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling. Cell Signal. 2021;88:110167.
   PubMed Web of Science ®Google Scholar
• Schmitt A, et al. Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL. Blood. 2021;138(10):871–884.
   PubMed Web of Science ®Google Scholar
• Campanella A, et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica. 2013;98(6):971–979.
   PubMed Web of Science ®Google Scholar
• Bordini J, et al. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia. 2017;31(4):967–970.
   PubMed Web of Science ®Google Scholar
• Bordini J, et al. Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: a proof of concept for novel combination therapies. Cancers (Basel). 2020;12(4).
   PubMed Web of Science ®Google Scholar
• Holien, T., et al., Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur J Haematol. 2013. 91(4): p. 339-346.
   PubMed Web of Science ®Google Scholar